BlossomHill Therapeutics, Inc.
corporate_fare Company Profile
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for BLSM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for BLSM spans 8-K, SCHEDULE 13D, 4, 424B4.
Recent high-impact activity:
- BlossomHill Posts $24.0M Q3 Loss; Pivotal SOLARA-2 Dosing Set for Q1 2027
- BlossomHill Aligns With FDA on Phase 2 Dose, Launches Pivotal SOLARA-2 Trial
- BlossomHill Posts $8.75 Q2 Loss Per Share in First Report Since IPO
- BlossomHill's BH-30643 Shows 45% ORR in EGFR C797S NSCLC, Phase 2 Planned for 2027
- OrbiMed Reveals 8.9% Stake in BlossomHill Post-IPO, Alongside Board Influence and Registration Rights
Short Interest & Short Volume
4.65 days to coverFINRA reported short interest of 590,133 shares in BLSM as of the October 30, 2026 settlement, a 21.7% increase from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 65.9% of BLSM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BLSM, detected from its recent SEC filings · based on capital-structure filings through 2026-08-07.
IPO Pricing · Use of Proceeds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →